BIOTECHNOLOGY

Micron Biomedical reports their applicator-free technology is well-suited for the administration of vaccines and, in particular, for measles-rubella vaccination in low- and middle-income countries.

ImmunoGen, Inc. is a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer.

Project RE will focus on finding therapies to tackle viral entry and replication and is co-led between Mila (Quebec AI Institute) and Relation Therapeutics, with the overall scientific direction by Mila founder Professor Yoshua Bengio.

Vitanova Biomedical is developing a prostate-specific membrane antigen targeted drug, VNBp-1, formulated as a first line treatment for local stage prostate cancer.

The initial contract is for 8 months. Todos has also been granted a priority right to supply the lab with up to 75,000 COVID PCR tests per day in the event the laboratory sees significant additional testing demand.

The broadcast, titled ‘Can We Cure Cancer With Artificial Intelligence?’, is available for on-demand viewing on the DojoLIVE! website.

As the sole distributor of SAMIX mixing machines to the compounding market in the United States and Canada, MEDISCA, a global leader in the...

William ‘Obi’ Greenman, Cerus’ president and chief executive officer explains, “This is a significant milestone for Cerus and highlights the scope our technology has had within the transfusion industry and on the millions of patients worldwide transfused with INTERCEPT treated platelet and plasma components. “We have a solid track record with the safety and efficacy of our INTERCEPT products, which now surpasses more than 7.5 million treatable doses.” 

Under the terms of the agreements, PATHNOVA will be responsible for the further development and commercialization of the Todos Tests in Singapore, and Todos Medical will assist PATHNOVA in commercializing its nasopharyngeal cancer tests through its affiliates in the United States and Singapore.